Skip to main content

Advertisement

Log in

Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer

Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Capecitabine is often offered as a first-line chemotherapy option for metastatic breast cancer (MBC). In this study, we compare characteristics of and survival among women prescribed first-line capecitabine or taxane monotherapy for MBC. Women receiving first-line chemotherapy for MBC from 1998 to 2005 were identified from the North Carolina tumor registry linked with Medicaid and Medicare claims records, and were followed through the end of 2005 with survival data from the National Death Index. T Tests and Chi-square tests were used to compare baseline characteristics. Overall survival and cancer-specific survival were examined using Cox proportional hazard modeling. There were 257 patients with MBC starting first-line chemotherapy with capecitabine (n = 71) or a taxane (n = 186). No differences in age, race, or Charlson comorbidity status were observed between groups. Hormone receptor negative tumors (31.0 vs. 17.7 %, p = 0.02) and patients insured by Medicaid (28 vs. 12 %, p = 0.002) were more prevalent in the capecitabine group. Time from metastasis to first-line chemotherapy was longer in the capecitabine group (52 vs. 26 % began after 3 months, p < 0.001). In multivariate analysis, treatment received was not associated with overall or cancer-specific survival. Among standard demographics, age was the only factor significantly associated with overall survival (HR 1.02, p = 04). In this population-based study, women who received capecitabine as first-line treatment for MBC were more often hormone receptor negative and insured by Medicaid. In multivariate analysis, first-line capecitabine and taxane for MBC yielded similar overall and cancer-specific survival outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Brewster AM, Hortobagyi GN, Broglio KR et al (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100:1179–1183

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  3. Verma S, Clemons M (2007) First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 12:785–797

    Article  PubMed  CAS  Google Scholar 

  4. Carrick S, Parker S, Thornton CE et al (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 15:CD003372

    Google Scholar 

  5. Cardoso F, Bedard PL, Winer EP et al (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174–1181

    Article  PubMed  CAS  Google Scholar 

  6. Network NCC (2010) NCCN clinical practice guidelines in oncology 5th edn. Breast Cancer

  7. Berthold D. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 21:665

  8. Tkaczuk KH (2009) Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 31(2):2273–2289

    Article  PubMed  Google Scholar 

  9. Perez EA (1998) Paclitaxel in breast cancer. Oncologist 3:373–389

    PubMed  CAS  Google Scholar 

  10. Seidman AD, Berry D, Cirrincione C et al (2004) Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3 h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for trastuzumab in HER2 normal MBC. Proc Am Soc Clin Oncol 22:6s

    Google Scholar 

  11. Ghersi D, Wilcken N, Simes RJ (2005) A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93:293–301

    Article  PubMed  CAS  Google Scholar 

  12. Gick U, Rochlitz C, Mingrone W et al (2006) Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology 71:54–60

    Article  PubMed  CAS  Google Scholar 

  13. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential versus combined therapy results from a MOSG randomized phase III trial. Proc Am Soc Clin Oncol 24:571

    Google Scholar 

  14. Stockler M, Sourjina T, Grimison P, Gebski V, Byrne M, Harvey V, Francis P, Nowak AK, Van Hazel G, Forbes J (2007) ANZ Breast Cancer Trials Group A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 25(18):1031

    Google Scholar 

  15. Jones A, O’Brien M, Sommer H et al (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65:755–763

    Article  PubMed  CAS  Google Scholar 

  16. Benekli M, Yildiz R, Uner A et al (2007) Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 72:308–313

    Article  PubMed  CAS  Google Scholar 

  17. Lamont EB, Herndon JE 2nd, Weeks JC et al (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335–1338

    Article  PubMed  Google Scholar 

  18. D’Hoore W, Bouckaert A, Tilquin C (1996) Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 49:1429–1433

    Article  PubMed  Google Scholar 

  19. Talbot DC, Moiseyenko V, Van Belle S et al (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367–1372

    Article  PubMed  CAS  Google Scholar 

  20. Gornas M, Szczylik C (2010) Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process? Eur J Cancer Care (Engl) 19:131–136

    Article  CAS  Google Scholar 

  21. Schwartzberg LS, Cobb P, Walker MS et al (2009) Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. Support Care Cancer 17:1081–1088

    Article  Google Scholar 

  22. Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649

    Article  PubMed  CAS  Google Scholar 

  23. Fountzilas G, Dafni U, Dimopoulos MA et al (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87–99

    Article  PubMed  CAS  Google Scholar 

  24. Beuselinck B, Wildiers H, Wynendaele W et al (2010) Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol 75:70–77

    Article  PubMed  Google Scholar 

Download references

Funding

The study was funded by Roche.

Conflict of interest

Drs. Kamal, Kimmick, Anderson, Camacho, and Balkrishnan have nothing to disclose. Dr. Wei was an employee of Roche during the period of the study analysis, who provided funding for the study. Dr. Wei was involved in the design of the study but did not participate in data collection or analysis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. H. Kamal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamal, A.H., Camacho, F., Anderson, R. et al. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 134, 371–378 (2012). https://doi.org/10.1007/s10549-012-2037-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2037-1

Keywords

Navigation